Human in vivo De Novo and Recall Antibody Responses after Rituximab Treatment for Type 1 Diabetes

被引：0
|
作者：
Pescovitz, Mark [1 ]
McGee, Paula [2 ]
Krause-Steinrauf, Heidi [2 ]
Canniff, Jennifer [3 ]
Weinberg, Adriana [3 ]
Skyler, Jay [4 ]
机构：
[1] Indiana Univ, Indianapolis, IN 46204 USA
[2] George Washington Univ, Rockville, MD USA
[3] Univ Colorado, Denver, CO 80202 USA
[4] Univ Miami, Miami, FL USA
来源：
CLINICAL IMMUNOLOGY | 2010年 / 135卷
关键词：
D O I：
10.1016/j.clim.2010.03.099
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：S32 / S32
页数：1
相关论文
共 50 条
  • [1] In Vivo Immune Responses in Type 1 Diabetes Following Treatment with Rituximab
    Pescovitz, Mark D.
    Torgerson, Troy R.
    Ochs, Hans D.
    Ocheltree, Elizabeth
    McGee, Paula
    Krause-Steinrauf, Heidi
    DIABETES, 2009, 58 : A51 - A51
  • [2] Effect of rituximab on human in vivo antibody immune responses
    Pescovitz, Mark D.
    Torgerson, Troy R.
    Ochs, Hans D.
    Ocheltree, Elizabeth
    McGee, Paula
    Krause-Steinrauf, Heidi
    Lachin, John M.
    Canniff, Jennifer
    Greenbaum, Carla
    Herold, Kevan C.
    Skyler, Jay S.
    Weinberg, Adriana
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2011, 128 (06) : 1295 - U655
  • [3] Ibrutinib Suppresses De Novo Alloantibodies and Recall Antibody Responses in a Mouse Model of Allosensitization: A Preliminary Report
    Wu, G. D.
    Kim, I.
    Chai, N.
    Klein, A. S.
    Jordan, S.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2016, 35 (04): : S93 - S93
  • [4] De novo mutation of PHEX in a type 1 diabetes patient
    Fang, Chen
    Li, Hui
    Li, Xiaozhen
    Xiao, Wenjin
    Huang, Yun
    Cai, Wu
    Yang, Yi
    Hu, Ji
    JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, 2016, 29 (05): : 621 - 626
  • [5] Pharmacokinetics and Antibody Responses to the CD3 Antibody Otelixizumab Used in the Treatment of Type 1 Diabetes
    Hale, Geoff
    Rebello, Peppy
    Al Bakir, Ibrahim
    Bolam, Emma
    Wiczling, Pawel
    Jusko, William J.
    Vandemeulebroucke, Evy
    Keymeulen, Bart
    Mathieu, Chantal
    Ziegler, Annette-G
    Chatenoud, Lucienne
    Waldmann, Herman
    JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 50 (11): : 1238 - 1248
  • [6] Evolving Antibody Therapies for the Treatment of Type 1 Diabetes
    Ke, Qi
    Kroger, Charles J.
    Clark, Matthew
    Tisch, Roland M.
    FRONTIERS IN IMMUNOLOGY, 2021, 11
  • [7] Exenatide and etanercept in De Novo islet transplantation for type 1 diabetes.
    Salehi, Payam
    Gangemi, Antonio
    Hatipoglu, Betul
    Martellotto, Joan
    Barbaro, Barbara
    Kuechle, Joseph
    Qi, Meirigeng
    Wang, Yong
    Pallan, Pablo
    Owens, Charles
    Bui, James
    West, Derek
    Kaplan, Bruce
    Benedetti, Enrico
    Oberholzer, Jose
    AMERICAN JOURNAL OF TRANSPLANTATION, 2008, 8 : 236 - 236
  • [8] De novo Anti-HLA Antibody Responses after Renal Transplantation: Detection and Clinical Impact
    Seveso, Michela
    Bosio, Erika
    Ancona, Ermanno
    Cozzi, Emanuele
    HUMORAL IMMUNITY IN KIDNEY TRANSPLANTATION: WHAT CLINICIANS NEED TO KNOW, 2009, 162 : 87 - 98
  • [9] High incidence of de novo diabetes mellitus type 1 during or after treatment with pegylated interferon in patients with chronic hepatitis C virus infection
    Schreuder, T. C. M. A.
    Gelderblom, H. G.
    Weegink, C. J.
    Reesink, H. W.
    Hoekstra, J. B. L.
    Jansen, P. L. M.
    JOURNAL OF HEPATOLOGY, 2006, 44 : S225 - S225
  • [10] High incidence of de novo diabetes mellitus type 1 during or after treatment with pegylated interferon in patients with chronic hepatitis C virus infection
    Hoekstra, J.
    Schreuder, T.
    Gelderblom, H.
    Weegink, C.
    Reesink, H.
    DeVries, J.
    Jansen, P.
    DIABETOLOGIA, 2006, 49 : 501 - 502
12345